Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study

PURPOSE: The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous no...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keunchil, Cho, Eun Kyung, Bello, Maximino, Ahn, Myung-Ju, Thongprasert, Sumitra, Song, Eun-Kee, Soldatenkova, Victoria, Depenbrock, Henrik, Puri, Tarun, Orlando, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654161/
https://www.ncbi.nlm.nih.gov/pubmed/28111429
http://dx.doi.org/10.4143/crt.2016.423

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654161/
https://www.ncbi.nlm.nih.gov/pubmed/28111429
http://dx.doi.org/10.4143/crt.2016.423

Ejemplares similares